M. Hughes

D. Katzenstein, M. Hughes, T. Merigan, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection.

M. Hughes, J. Oleske, S. Nachman, 2004, Pediatrics.

Hospitalizations Among Children and Youths With Human Immunodeficiency Virus Infection

M. Hughes, J. Oleske, S. Nachman, 2004 .

Evaluating surrogate endpoints.

M. Hughes, 2002, Controlled clinical trials.

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

M. Hughes, R. Schooley, R. Gross, 2019, The lancet. HIV.

Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women

M. Hughes, L. Mofenson, P. Deutsch, 2006, Antimicrobial Agents and Chemotherapy.

Virologic and CD 4 1 Cell Responses to New Nucleoside Regimens : Switching to Stavudine or Adding Lamivudine after Prolonged Zidovudine Treatment of Human Immunodeficiency Virus Infection

S. Hammer, D. Katzenstein, M. Hughes, 2004 .

Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults.

M. Hughes, R. Peto, T. Peto, 2000, The Cochrane database of systematic reviews.

Clinical Response and Tolerability to and Safety of Saquinavir with Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Mothers and Their Infants

M. Hughes, L. Mofenson, E. Acosta, 2007, Antimicrobial Agents and Chemotherapy.

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

M. Hughes, D. Kuritzkes, C. Flexner, 2009, The Journal of infectious diseases.

Pharmacokinetic/Pharmacodynamic Modeling of the Antiretroviral Activity of the CCR5 Antagonist Vicriviroc in Treatment Experienced HIV-Infected Subjects (ACTG Protocol 5211)

M. Hughes, D. Kuritzkes, C. Flexner, 2010, Journal of acquired immune deficiency syndromes.

Outcomes among HIV-1 Infected Individuals First Starting Antiretroviral Therapy with Concurrent Active TB or Other AIDS-Defining Disease

M. Hughes, U. Lalloo, T. Flanigan, 2013, PloS one.

Targeted HIV testing at birth supported by low and predictable mother‐to‐child transmission risk in Botswana

M. Hughes, D. Kuritzkes, S. Lockman, 2018, Journal of the International AIDS Society.

Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.

M. Hughes, B. Chi, J. Lindsey, 2012, The New England journal of medicine.

Antiretroviral treatment for children with peripartum nevirapine exposure.

M. Hughes, B. Chi, J. Lindsey, 2010, The New England journal of medicine.

Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US

Milton C Weinstein, Taige Hou, A David Paltiel, 2015, HIV clinical trials.

In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children

M. Hughes, L. Mofenson, G. Seage, 2007, AIDS.

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject

Francoise F Giguel, M. Hughes, D. Kuritzkes, 2008, Journal of Virology.

Factors Associated With Lack of Viral Suppression at Delivery Among Highly Active Antiretroviral TherapyNaive Women With HIV

M. Hughes, I. Katz, E. Leister, 2015, Annals of Internal Medicine.

Quality of Life for Children and Adolescents: Impact of HIV Infection and Antiretroviral Treatment

M. Hughes, S. Gortmaker, J. Oleske, 2006, Pediatrics.

Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1–Infected Individuals: SWIFT-C

M. Hughes, R. Chung, D. Fierer, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding.

M. Hughes, N. Mcintyre, A. Burroughs, 1990, Gastroenterology.

Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding

M. Hughes, N. Mcintyre, A. Burroughs, 1990 .

Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer

M. Hughes, 2008, Statistical methods in medical research.

Safety and Pharmacokinetics of Nelfinavir Coadministered With Zidovudine and Lamivudine in Infants During the First 6 Weeks of Life

M. Hughes, L. Mofenson, J. Connor, 2005, Journal of acquired immune deficiency syndromes.

Efficacy, Tolerability and Pharmacokinetics of Two Nelfinavir-Based Regimens in Human Immunodeficiency Virus-Infected Children and Adolescents: Pediatric AIDS Clinical Trials Group Protocol 403

M. Hughes, G. Aldrovandi, E. Acosta, 2005, The Pediatric infectious disease journal.

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy

M. Hughes, T. Flanigan, L. Smeaton, 2016, HIV clinical trials.

Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy

M. Hughes, R. Yogev, E. Capparelli, 2011, AIDS.

Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients

M. Hughes, M. Hirsch, D. Kuritzkes, 2010, Journal of acquired immune deficiency syndromes.

Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.

M. Hughes, J. Lindsey, S. Spector, 2004, The Journal of infectious diseases.

Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.

M. Hughes, R. Gross, J. Mellors, 2019, The Lancet. Digital health.

Lipid and Glucose Alterations in HIV-Infected Children Beginning or Changing Antiretroviral Therapy

M. Hughes, C. Chantry, W. Meyer, 2008, Pediatrics.

Feasibility of Identifying Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease.

M. Hughes, S. Swindells, U. Lalloo, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cotrimoxazole prophylaxis was associated with enteric commensal bacterial resistance among HIV‐exposed infants in a randomized controlled trial, Botswana

M. Hughes, S. Lockman, M. Essex, 2017, Journal of the International AIDS Society.

Associations of Chemokine Receptor Polymorphisms With HIV-1 Mother-to-Child Transmission in Sub-Saharan Africa: Possible Modulation of Genetic Effects by Antiretrovirals

M. Hughes, S. Spector, C. Rousseau, 2008, Journal of acquired immune deficiency syndromes.

Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial.

M. Hughes, S. Lockman, K. Mcintosh, 2017, The Lancet. Global health.

Genetic polymorphisms in CX3CR1 predict HIV-1 disease progression in children independently of CD4+ lymphocyte count and HIV-1 RNA load.

M. Hughes, S. Spector, K. Singh, 2005, The Journal of infectious diseases.

Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.

M. Hughes, A. Randolph, C. Fichtenbaum, 2019, The Lancet. Respiratory medicine.

Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.

M. Hughes, I. Thior, M. Essex, 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Dutch CNSLD Study Group.

M. Hughes, E. Duiverman, K. Kerrebijn, 1994, The European respiratory journal.

Vitamin D Insufficiency in HIV-infected Pregnant Women Receiving Antiretroviral Therapy is Not Associated With Morbidity, Mortality or Growth Impairment in Their Uninfected Infants in Botswana

M. Hughes, W. Fawzi, S. Lockman, 2014, The Pediatric infectious disease journal.

A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings

M. Hughes, K. Erlandson, L. Smeaton, 2015, Open forum infectious diseases.

Challenges in using observational studies to evaluate adverse effects of treatment.

Paige L. Williams, M. Hughes, P. Williams, 2007, The New England journal of medicine.

Prevalence of Chemokine and Chemokine Receptor Polymorphisms in Seroprevalent Children With Symptomatic HIV-1 Infection in the United States

M. Hughes, S. Spector, K. Singh, 2004, Journal of acquired immune deficiency syndromes.

Remission oof cchildhood aasthma aafter llong-term treatment w with aan iinhaled ccorticosteroid ((budesonide): C Can iit bbe achieved?

M. Hughes, E. Duiverman, K. Kerrebijn, 1994 .

A Randomized Double-Blind Phase 2 Study of Combination Antivirals for the Treatment of Influenza

M. Hughes, R. Schooley, R. Davey, 2017, The Lancet. Infectious diseases.

A Randomized Double-Blind Phase 2 Study of Combination Antivirals for the Treatment of Influenza

M. Hughes, R. Davey, H. Lane, 2017, The Lancet. Infectious diseases.

CCR5/Δccr5 Heterozygosity: A Selective Pressure for the Syncytium-Inducing Human Immunodeficiency Virus Type 1 Phenotype

M. Hughes, V. Johnson, R. D’Aquila, 1998 .

Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. The Dutch CNSLD Study Group.

M. Hughes, H. Kerstjens, E. Duiverman, 1993, The American review of respiratory disease.

Sample size estimation for stratified individual and cluster randomized trials with binary outcomes

M. Hughes, L. Kennedy‐Shaffer, 2020, Statistics in medicine.

Impact of MCP-1-2518-G allele on the HIV-1 disease of children in the United States.

M. Hughes, S. Spector, K. Singh, 2006, AIDS.

High Viral Load and Elevated Angiogenic Markers Associated With Increased Risk of Preeclampsia Among Women Initiating Highly Active Antiretroviral Therapy in Pregnancy in the Mma Bana Study, Botswana

M. Hughes, S. Lockman, T. McElrath, 2013, Journal of acquired immune deficiency syndromes.

Delayed Onset of Pubertal Development in Children and Adolescents With Perinatally Acquired HIV Infection

M. Hughes, J. Lindsey, K. Buchacz, 2003, Journal of acquired immune deficiency syndromes.

Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine

M. Hughes, J. Mellors, J. Coffin, 2011, Proceedings of the National Academy of Sciences.

A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.

M. Hughes, M. Widdowson, F. Dawood, 2016, Antiviral research.

Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults.

M. Hughes, R. Peto, T. Peto, 2000, The Cochrane database of systematic reviews.

Long Term Tolerability and Safety of Enfuvirtide for Human Immunodeficiency Virus 1-Infected Children

M. Hughes, J. Church, L. Mofenson, 2004, The Pediatric infectious disease journal.

Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.

M. Hughes, T. Flanigan, T. Campbell, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

IMMUNE DONORS CAN PROTECT MARROW-TRANSPLANT RECIPIENTS FROM SEVERE CYTOMEGALOVIRUS INFECTIONS

M. Hughes, H. Prentice, M. Brenner, 1987, The Lancet.

HIV testing uptake among the household contacts of multidrug-resistant tuberculosis index cases in eight countries.

M. Hughes, S. Swindells, R. Dawson, 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Variability and Prognostic Values of Virologic and CD4 Cell Measures in Human Immunodeficiency Virus Type 1‐Infected Patients with 200–500 CD4 Cells/mm3(ACTG 175)

S. Hammer, D. Katzenstein, M. Hughes, 1998, The Journal of Infectious Diseases.

Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003).

M. Hughes, S. Swindells, R. Dawson, 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

HIV Clinical Trials: Important Concepts and Questions

M. Hughes, D. Kuritzkes, P. Sax, 2005 .

Viral Reservoir in Early-Treated HIV-Infected Children and Markers for Sustained Viral Suppression.

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women

M. Hughes, S. Lockman, J. Currier, 2012, AIDS.

Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy.

M. Hughes, S. Lockman, D. Kitch, 2011, The Journal of infectious diseases.

Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.

M. Hughes, K. Tashima, R. Paredes, 2009, Clinical Infectious Diseases.

Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group.

M. Hughes, S. Pocock, E. Duiverman, 1992, The American review of respiratory disease.

A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group.

D. Postma, M. Hughes, E. Bleecker, 1992, The New England journal of medicine.

Resistance to Mycobacterium tuberculosis infection among household contacts: a multinational study.

M. Hughes, S. Swindells, G. Churchyard, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

M. Hughes, E. Daar, Davey M. Smith, 2022, Cell reports. Medicine.

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

M. Hughes, E. Daar, Davey M. Smith, 2021, medRxiv.

The impact of psoriasis on pregnancy outcomes.

A. Kimball, M. Hughes, Vanitha Janakiraman, 2012, The Journal of investigative dermatology.

Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19

A. Perelson, M. Hughes, W. Fischer, 2021, medRxiv.

High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis

M. Hughes, S. Swindells, A. Demers, 2022, The Pediatric infectious disease journal.

Pharmacokinetics and Safety of Nelfinavir When Used in Combination with Zidovudine and Lamivudine in HIV-Infected Pregnant Women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353

M. Hughes, L. Mofenson, J. Connor, 2008, HIV clinical trials.

Antiretroviral therapies in women after single-dose nevirapine exposure.

M. Hughes, R. Schooley, J. Mellors, 2010, The New England journal of medicine.

Mother-to-Child HIV Transmission with in utero Dolutegravir vs. Efavirenz in Botswana.

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2020, Journal of acquired immune deficiency syndromes.

Major Clinical Outcomes in Antiretroviral Therapy (ART)-Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study. Commentary

M. Hughes, H. Ribaudo, 2008 .

SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ANTIRETROVIRAL THERAPY.

M. Hughes, R. Gross, A. Collier, 2020, Journal of acquired immune deficiency syndromes.

Bone Mineral Density Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor Selection from ACTG A5142

Jeannie S. Huang, M. Hughes, R. Haubrich, 2013, HIV clinical trials.

Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children

M. Hughes, J. Church, L. Mofenson, 2002, The Pediatric infectious disease journal.

Decreased diarrheal and respiratory disease in HIV exposed uninfected children following vaccination with rotavirus and pneumococcal conjugate vaccines

M. Hughes, S. Lockman, R. Shapiro, 2020, PloS one.

Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.

M. Hughes, S. Gortmaker, G. Seage, 2001, The New England journal of medicine.

Neurodevelopment and In Utero Antiretroviral Exposure of HIV-Exposed Uninfected Infants

Paige L. Williams, M. Hughes, L. Mofenson, 2010, Pediatrics.

The prevalence of pain in pediatric human immunodeficiency virus/acquired immunodeficiency syndrome as reported by participants in the Pediatric Late Outcomes Study (PACTG 219).

M. Hughes, S. Gortmaker, P. Selwyn, 2002, Pediatrics.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

M A Fischl, M D Hughes, S. Hammer, 1997, The New England journal of medicine.

Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response

M. Hughes, M. Hirsch, V. Johnson, 1997, Annals of Internal Medicine.

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

S. Hammer, D. Katzenstein, M. Hughes, 1996, The New England journal of medicine.

Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients

Lewis B. Sheiner, Martin S. Hirsch, Victoria A. Johnson, 1999, Antimicrobial Agents and Chemotherapy.

Significant bacteriuria has prognostic significance in primary biliary cirrhosis.

M. Hughes, N. Mcintyre, A. Burroughs, 1989, Journal of Hepatology.

Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261)

M. Hughes, M. Hirsch, M. Fischl, 1999 .

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.

S. Hammer, D. Katzenstein, M. Hughes, 1998, The Journal of infectious diseases.

Antiretroviral regimens in pregnancy and breast-feeding in Botswana.

M. Hughes, A. Act, S. Lockman, 2010, The New England journal of medicine.

Increased Risk of Severe Infant Anemia After Exposure to Maternal HAART, Botswana

M. Hughes, S. Lockman, S. Dryden-Peterson, 2011, Journal of acquired immune deficiency syndromes.

Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women

M. Hughes, L. Mofenson, E. Acosta, 2004, Antimicrobial Agents and Chemotherapy.

Long-term Safety and Efficacy of a Once-Daily Regimen of Emtricitabine, Didanosine, and Efavirenz in HIV-Infected, Therapy-Naive Children and Adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021

M. Hughes, S. Spector, Chengcheng Hu, 2007, Pediatrics.

M. Hughes, M. Hirsch, M. Fischl, 1999, Journal of acquired immune deficiency syndromes.

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.

S. Hammer, D. Katzenstein, M. Hughes, 2000, AIDS research and human retroviruses.

Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.

M. Hughes, R. Schooley, J. Mellors, 2014, The Journal of infectious diseases.

Randomized Controlled Trial of Feeding a Concentrated Formula to Infants Born to Women Infected by Human Immunodeficiency Virus

M. Hughes, J. Oleske, R. McKinney, 2009, Journal of pediatric gastroenterology and nutrition.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

M. Hughes, G. Seage, S. Nachman, 2006, Archives of pediatrics & adolescent medicine.

Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.

M. Hughes, J. Mellors, J. Hitti, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial

M. Hughes, M. Hosseinipour, J. Kumwenda, 2018, Journal of acquired immune deficiency syndromes.

Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa

M. Hughes, S. Lockman, J. Currier, 2014, BMC Infectious Diseases.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

M. Hughes, C. Giaquinto, L. Mofenson, 2011, The Lancet. Infectious diseases.

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.

D. Katzenstein, M. Hughes, R. Shafer, 2002, Journal of acquired immune deficiency syndromes.

Cotrimoxazole Prophylaxis and Risk of Severe Anemia or Severe Neutropenia in HAART-Exposed, HIV-Uninfected Infants

M. Hughes, S. Lockman, K. Mcintosh, 2013, PloS one.

Neuromuscular function in HIV infection: analysis of a placebo‐controlled combination antiretroviral trial

S. Hammer, D. Katzenstein, M. Hughes, 1998, AIDS.

Early Initiation of Lopinavir/Ritonavir in Infants Less Than 6 Weeks of Age: Pharmacokinetics and 24-Week Safety and Efficacy

M. Hughes, R. Yogev, E. Capparelli, 2009, The Pediatric infectious disease journal.

Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children.

M. Hughes, J. Lindsey, K. Buchacz, 2001, Pediatrics.

Associations of Proinflammatory Cytokine Levels With Lipid Profiles, Growth, and Body Composition in HIV-infected Children Initiating or Changing Antiretroviral Therapy

M. Hughes, S. Spector, C. Chantry, 2010, The Pediatric infectious disease journal.

Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children.

M. Cowles, M. Hughes, J. Lindsey, 2000, The Journal of infectious diseases.

Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection

M. Hughes, R. Shafer, G. Robbins, 2010, AIDS.

Antiretroviral therapy during pregnancy and the risk of an adverse outcome.

M. Hughes, L. Mofenson, D. Wara, 2002, The New England journal of medicine.

Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.

S. Hammer, D. Katzenstein, M. Hughes, 2000, AIDS Research and Human Retroviruses.

The search for data on when to start treatment for HIV infection.

M. Hughes, H. Ribaudo, 2008, The Journal of infectious diseases.

Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.

S. Hammer, D. Katzenstein, M. Hughes, 2001, AIDS research and human retroviruses.

Virologic and CD 4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment of Human Immunodeficiency Virus Infection

D. Katzenstein, M. Hughes, S. Liou, 2004 .

HIV-1 Protease Inhibitors and Clinical Malaria: a Secondary Analysis of the AIDS Clinical Trials Group A5208 Study

S. Cole, M. Hughes, J. McCarthy, 2011, Antimicrobial Agents and Chemotherapy.

Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

S. Hammer, D. Katzenstein, M. Hughes, 2000, AIDS research and human retroviruses.

Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.

S. Hammer, D. Katzenstein, M. Hughes, 1998, The Journal of infectious diseases.

Long-term clinical, immunologic, and virologic outcomes among early-treated children with HIV in Botswana: a nonrandomized controlled clinical trial.

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2022, Journal of acquired immune deficiency syndromes.

Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children

M. Hughes, D. Harris, C. Giaquinto, 2010, AIDS.

Predictors of Virologic and Clinical Response to Nevirapine versus Lopinavir/Ritonavir-based Antiretroviral Therapy in Young Children With and Without Prior Nevirapine Exposure for the Prevention of Mother-to-child HIV Transmission

M. Hughes, J. Lindsey, L. Mofenson, 2014, The Pediatric infectious disease journal.

Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term observation of adolescents initiating HAART therapy: three-year follow-up.

M. Hughes, J. Lindsey, S. Spector, 2007, AIDS research and human retroviruses.

Neurodevelopmental Functioning in HIV-Infected Infants and Young Children Before and After the Introduction of Protease Inhibitor–Based Highly Active Antiretroviral Therapy

M. Hughes, J. Lindsey, K. Malee, 2007, Pediatrics.

HIV diagnostic algorithm requires confirmatory testing for initial indeterminate or positive screens in the first week of life.

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2020, AIDS.

Dynamics of the resting CD4+ T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age

M. Hughes, D. Persaud, R. Yogev, 2012, AIDS.

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.

M. Hughes, R. Haubrich, P. Sax, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2022, Journal of acquired immune deficiency syndromes.

Linked dual-class HIV resistance mutations are associated with treatment failure.

M. Hughes, R. Schooley, J. Mellors, 2019, JCI insight.

PEDIATRIC AIDS CLINICAL TRIALS GROUP PROTOCOL 219 TEAM. EFFECT OF COMBINATION THERAPY INCLUDING PROTEASE INHIBITORS ON MORTALITY AMONG CHILDREN AND ADOLESCENTS INFECTED WITH HIV-1

Michael T. Brady, Steven L. Gortmaker, M. Hughes, 2001 .

Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults

M. Hughes, R. Haubrich, J. Mellors, 2018, PloS one.

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

M. Hughes, R. Chung, D. Fierer, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk Factors for Detectable HIV-1 RNA at Delivery Among Women Receiving Highly Active Antiretroviral Therapy in the Women and Infants Transmission Study

M. Hughes, Usha Govindarajulu, I. Katz, 2010, Journal of acquired immune deficiency syndromes.

Increased Risk of Preterm Delivery Among HIV-Infected Women Randomized to Protease Versus Nucleoside Reverse Transcriptase Inhibitor–Based HAART During Pregnancy

M. Hughes, S. Lockman, D. Kitch, 2011 .

Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings

M. Hughes, A. Collier, Linda J Harrison, 2018, AIDS care.

HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana

M. Hughes, S. Lockman, D. Kitch, 2013, AIDS.

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial

Kenneth A. Freedberg, Rochelle P. Walensky, Milton C. Weinstein, 2012, AIDS.

Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring.

D S Stein, M D Hughes, M. Hughes, 1994, The Journal of infectious diseases.

Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.

S. Hammer, D. Katzenstein, M. Hughes, 1998, The Journal of infectious diseases.

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Eoin Coakley, Robert Gross, Wayne Greaves, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lack of protective effects of interleukin-4 -589-C/T polymorphism against HIV-1-related disease progression and central nervous system impairment, in children.

M. Hughes, S. Spector, K. Singh, 2004, The Journal of infectious diseases.

Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection.

M. Hughes, S. Spector, K. Singh, 2003, The Journal of infectious diseases.

Osteonecrosis of the hip (Legg-Calvé-Perthes disease) in human immunodeficiency virus-infected children.

M. Hughes, L. Mofenson, G. Seage, 2002, Pediatrics.

Willingness to Take Multidrug-Resistant Tuberculosis (MDR-TB) Preventive Therapy among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multi-Site Cross-Sectional Study.

M. Hughes, S. Swindells, U. Lalloo, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings

M. Hughes, A. Collier, Linda J Harrison, 2021, AIDS care.

Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons

M. Hughes, Amita Gupta, A. Hesseling, 2019, PLoS medicine.

Assessing Human Immunodeficiency Virus Type 1 Tropism: Comparison of Assays Using Replication-Competent Virus versus Plasma-Derived Pseudotyped Virions

M. Hughes, D. Kuritzkes, C. Flexner, 2009, Journal of Clinical Microbiology.

Detection of Replication-Competent Human Immunodeficiency Virus Type 1 (HIV-1) in Cultures from Patients with Levels of HIV-1 RNA in Plasma Suppressed to Less Than 500 or 50 Copies Per Milliliter

S. Hammer, M. Hughes, V. Johnson, 2002, Journal of Clinical Microbiology.

Insulin-Like Growth Factor-1 and Lean Body Mass in HIV-Infected Children

M. Hughes, C. Chantry, P. Borum, 2008, Journal of acquired immune deficiency syndromes.

Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment.

J. Ioannidis, M. Hughes, P. Volberding, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

An Augmented SMS Intervention to Improve Access to Antenatal CD4 Testing and ART Initiation in HIV-Infected Pregnant Women: A Cluster Randomized Trial

M. Hughes, A. Veres, M. Siedner, 2015, PloS one.

M. Hughes, S. Lockman, K. Mcintosh, 2018, Southern African journal of HIV medicine.

Immunodeficiency Virus-Infected Patients Zidovudine, and Didanosine in Human Population Pharmacokinetics of Nevirapine,

M. Hughes, M. Hirsch, V. Johnson, 2013 .

Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine

M. Hughes, A. Siika, S. Lockman, 2014, AIDS.

A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.

S. Hammer, M. Hughes, S. Suwanagool, 2000, Australian and New Zealand journal of medicine.

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate

M. Hughes, R. Chung, D. Fierer, 2018, The Journal of antimicrobial chemotherapy.

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection

M. Hughes, C. Fletcher, J. Currier, 2022, Clinical pharmacology and therapeutics.

Assessing agreement in the timing of treatment initiation determined by repeated measurements of novel versus gold standard technologies with application to the monitoring of CD4 counts in HIV‐infected patients

M. Hughes, F. Noubary, 2010, Statistics in medicine.

Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.

M. Hughes, R. Peto, T. Peto, 2000, The Cochrane database of systematic reviews.

Stopping guidelines for clinical trials with multiple treatments.

M D Hughes, M. Hughes, 1993, Statistics in medicine.

Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women

M. Hughes, U. Lalloo, A. Collier, 2018, AIDS.

Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior.

Hulin Wu, M. Hughes, J. Lindsey, 2004, The Journal of infectious diseases.

First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial

M. Hughes, R. Walensky, K. Freedberg, 2011, AIDS.

Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial

M. Hughes, R. Schooley, J. Mellors, 2012, PLoS medicine.

Hyperlipidaemia in HIV-Infected Patients on Lopinavir/Ritonavir Monotherapy in Resource-Limited Settings

M. Hughes, J. Bartlett, M. Hosseinipour, 2016, Antiviral therapy.

Cardiovascular Disease Risk Factors in HIV-Infected Women After Initiation of Lopinavir/Ritonavir- and Nevirapine-Based Antiretroviral Therapy in Sub-Saharan Africa: A5208 (OCTANE)

M. Hughes, S. Lockman, J. Currier, 2014, Journal of acquired immune deficiency syndromes.

Factors Affecting Timing of Antiretroviral Treatment Initiation Based on Monitoring CD4 Counts

M. Hughes, F. Noubary, 2012, Journal of acquired immune deficiency syndromes.

Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials.

M. Hughes, H. Gundacker, P. Volberding, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

In-utero triple antiretroviral exposure associated with decreased growth among HIV-exposed uninfected infants in Botswana

M. Hughes, W. Fawzi, S. Lockman, 2016, AIDS.

Initial treatment of HIV infection: randomized trials with clinical end points are still needed.

M. Hughes, 2006, The Journal of infectious diseases.

Highly Active Antiretroviral Therapy Versus Zidovudine for Prevention of Mother-to-Child Transmission in a Programmatic Setting, Botswana

M. Hughes, S. Lockman, S. Dryden-Peterson, 2011, Journal of acquired immune deficiency syndromes.

Time to first positive HIV-1 DNA PCR may differ with antiretroviral regimen in infants infected with non-B subtype HIV-1

M. Hughes, S. Lockman, M. Fowler, 2017, AIDS.

Power considerations for clinical trials using multivariate time-to-event data.

M D Hughes, M. Hughes, 1997, Statistics in medicine.

CCR5/delta(ccr5) heterozygosity: a selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype. NIAID AIDS Clinical Trials Group Protocol 241 Virology Team.

M. Hughes, V. Johnson, R. D’Aquila, 1998, Journal of Infectious Diseases.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Tania B. Huedo-Medina, M. Hughes, P. Sax, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings.

M. Hughes, R. Gross, J. Mellors, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Estimation of the cumulative incidence function under multiple dependent and independent censoring mechanisms

M. Hughes, Shu Yang, J. Lok, 2018, Lifetime Data Analysis.

A Randomized Study of Immune Plasma for the Treatment of Severe Influenza

M. Hughes, C. Cairns, J. Metcalf, 2017 .

Failure of Initial Therapy With Two Nucleosides and Efavirenz Is Not Associated With Early Emergence of Mutations in the C-Terminus of HIV-1 Reverse Transcriptase

M. Hughes, R. Haubrich, J. Mellors, 2011, Journal of acquired immune deficiency syndromes.

Trials of Tuberculosis-Preventive Therapy in People with HIV Infection

M. Hughes, R. Chaisson, S. Swindells, 2020, American journal of respiratory and critical care medicine.

Issues in the Design of Long-Term Clinical Trials in Asthma

Michael D. Hughes, Huib A. M. Kerstjens, M. Hughes, 1993 .

The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients.

M. Hughes, B. Taiwo, S. Rosenkranz, 2013, AIDS research and human retroviruses.

Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.

M. Hughes, R. Schooley, J. Mellors, 2014, Journal of Infectious Diseases.

Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women

M. Hughes, S. Lockman, J. Currier, 2012, AIDS.

Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial

M. Hughes, S. Swindells, A. Demers, 2021, BMC Infectious Diseases.

Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection

M. Hughes, R. Shafer, G. Robbins, 2010, AIDS.

Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials.

M D Hughes, M. Hughes, 2000, Statistics in medicine.

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial

M. Hughes, R. Schooley, M. Weinstein, 2012, AIDS.

High Viral Load and Elevated Angiogenic Markers Associated With Increased Risk of Preeclampsia Among Women Initiating Highly Active Antiretroviral Therapy in Pregnancy in the Mma Bana Study, Botswana

M. Hughes, S. Lockman, T. McElrath, 2013, Journal of acquired immune deficiency syndromes.

Predictors of Virologic and Clinical Outcomes in HIV-1Infected Patients Receiving Concurrent Treatment with Indinavir, Zidovudine, and Lamivudine: AIDS Clinical Trials Group Protocol 320

S. Hammer, M. Hughes, S. Spector, 2001, Annals of Internal Medicine.

Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.

M. Hughes, B. Chi, J. Lindsey, 2012, The New England journal of medicine.

Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy.

M. Hughes, S. Lockman, D. Kitch, 2011, The Journal of infectious diseases.

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

M. Hughes, E. Daar, Davey M. Smith, 2022, Cell Reports Medicine.

Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy

M. Hughes, R. Yogev, E. Capparelli, 2011, AIDS.

Annals of internal medicine: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response

M. Hughes, V. Johnson, D. Kuritzkes, 1997 .

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

M. Hughes, D. Kuritzkes, C. Flexner, 2009, The Journal of infectious diseases.

Estimation of the cumulative incidence function under multiple dependent and independent censoring mechanisms

Shu Yang, Judith J Lok, M. Hughes, 2017, Lifetime Data Analysis.